Navigation Links
Medicago's H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose
Date:7/30/2009

QUEBEC CITY, July 30 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has achieved additional positive results with its vaccine candidate for the Influenza A (H1N1) virus, also known as Swine flu. Results showed that a single dose of 5 micrograms induced a positive immune response against a new emerging strain of this virus in 100% of vaccinated animals.

Medicago's H1N1 VLP vaccine was formulated to protect against the influenza A/California/04/09 virus ("California/04"), which was one of the original viral strains selected by the WHO for vaccine manufacturers. The Company previously reported data from an initial study in mice where its novel vaccine achieved a positive immune response in 100% of the animals vaccinated against the California/04 virus. In a continuation of this study, Medicago tested the immune response of its H1N1 vaccine against the California/07 virus, a more current and mutated strain and showed positive immune response after a single dose of 5 micrograms. The challenge of current pandemic influenza vaccines is they have to match the circulating strain in order to be effective.

"We have already demonstrated the speed of our technology by producing an H1N1 vaccine candidate and initiating animal testing while other vaccine manufacturers were still waiting for a seed strain from the WHO. These additional data expand upon the results we announced in June and support our belief that our influenza vaccines are also capable of providing protection against different circulating viral strains," said Andy Sheldon, President and CEO of Medicago. "Unlike current vaccine manufacturers that have experienced difficulties producing a pandemic candidate for H1N1, our H1N1 vaccine candidate was well expressed in our plant-based system and has produc
'/>"/>

SOURCE Medicago Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine
2. Vical Presentation at Military Pandemic Influenza Workshop
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. NASA technology helps predict and prevent future pandemic outbreaks
5. Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference
6. Experts and Representatives From Leading International Health-Care Organizations Call to Stop the Hypertension Pandemic, a Worldwide Silent Killer
7. NIH Funds Vaccine Research for Needle-free and Self-Administered Protection Against Pandemic Influenza
8. H1N1 Influenza Virus With Highest Replikin Count(TM) Since the 1918 Pandemic Identified in the U.S. and Austria
9. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
10. CEO Addresses Fort Worth Business Leaders About Developing Pandemic and Business Continuity Plans
11. Roche Introduces Program to Facilitate Corporate Pandemic Stockpiling of Tamiflu(R)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)..., SEATTLE, Nov. 19 Omero...udited financial results for the third quarter end...September 30, 2009, Omeros reported a net loss of ... net loss of $7.4 million, or $2.54 per share, for...d September 30, 2009, the Company reported a net l...
(Date:11/19/2009)..., ,, BETHESDA, Md., Nov. 19 /PRNewswire-F..., an innovator in biotechnology for diabetes thera...sulting services to food, supplement, biotechnolog... closed the previously reported $6.3 million regis...of 2,760,870 shares of its common stock and warran...
(Date:11/19/2009)..., BETHESDA, Md., Nov. 19 ...or in biotechnology for diabetes therapy, and a pr...ices to food, supplement, biotechnology and pharma... Tuesday,s Annual Meeting of Shareholders. ,, A...d (Nasdaq: SPEX ) elected the following members t...
(Date:11/19/2009)..., MUNSTER, Germany, November 19 /PRNewswire...e filed on November 16th, 2009 Flibanserin in the,...kinesia in Parkinson,s,disease for orphan drug sta...,(EMEA). Levodopa-induced dyskinesia is a complica...on,s and a serious burden to some of those,affecte...
Breaking Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2
... The Binding Site Limited,("The Binding Site" or ...diagnostics company, today announces the publicati...ing first-line use of Freelite(TM) in the,diagnosi...cells in the bone,marrow, and related plasma cell ...half of the International Myeloma,Working Group ("...
...t of an announcement made recently by Astellas Pha...confirmed that it had received a letter dated Nove...icited proposal by Astellas to acquire CV Therapeu...e diligence, Astellas board approval and other con...he assistance of its financial and legal advisors,...
... responds to the demand in food, beverage and nutr...ading specialty chemical company, Albemarle Corpor...mpany, Zymes LLC, have joined forces to scale-up p...solubilization technology, PTS. The next generati...n-water-soluble vitamins and natural functional in...
Other Biology Technology:International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 2International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 3International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 4International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 5International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 6International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia" 7CV Therapeutics Statement on Unsolicited Proposal From Astellas 2CV Therapeutics Statement on Unsolicited Proposal From Astellas 3Albemarle Manufactures Zymes' PTS, the Lead Compound in a Breakthrough Solubilization Technology 2Albemarle Manufactures Zymes' PTS, the Lead Compound in a Breakthrough Solubilization Technology 3
(Date:11/19/2009)...AFAYETTE, Ind. - Purdue University scientists have... responsible for cell wall development in maize, a...ys to produce the biomass best suited for biofuels...holas Carpita, a professor of plant cell biology, ...s in the journal Plant Physiology on Thursday (N...
(Date:11/19/2009)...LA, CA November 19, 2009 A team led by scientists... a direct link between insulina hormone long assoc... as diabetesand core body temperature. While much ...iscovery in the 1920s, this is the first time the ...ess of temperature regulation. , The paper was p...
(Date:11/19/2009)...E PARK, Md.-John Fisher, associate professor in th...est Inventor Pitch at the 2009 Bioscience Research...ng bioreactor system that grows bone and other typ...logy was one of six innovations presented in an ei...tudents at the Professor Venture Fair, held Novemb...
Breaking Biology News(10 mins):Maize cell wall genes identified, giving boost to biofuel research 2Scripps research scientists find new link between insulin and core body temperature 2Scripps research scientists find new link between insulin and core body temperature 3Scripps research scientists find new link between insulin and core body temperature 4Bioreactor for bone tissue engineering wins professor venture fair 2Bioreactor for bone tissue engineering wins professor venture fair 3With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 1With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 2With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 3With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 4With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 5With Economic Pain Contributing to Minor Strains and Sprains King Pharmaceuticals 28R 29 Inc and RealAge com Launch Effort to Educate Americans on 57759 6Minerva and Cymbalta Patent Invalidity Evidence Uncovered by Article One Partners Community 57757 1Minerva and Cymbalta Patent Invalidity Evidence Uncovered by Article One Partners Community 57757 2Minerva and Cymbalta Patent Invalidity Evidence Uncovered by Article One Partners Community 57757 3Keryx Biopharmaceuticals Inc to Hold Investor Analyst Day Tomorrow 57755 1Keryx Biopharmaceuticals Inc to Hold Investor Analyst Day Tomorrow 57755 2Keryx Biopharmaceuticals Inc to Hold Investor Analyst Day Tomorrow 57755 3
... the most severe form of that group of diseases, a...s caused by a protozoan, Leishmania infantum, tran... this disease, which can rapidly lead to death if ...d areas, the dog population is hit heavily by infe...evelopment of a vaccine for dogs could help brake ...
...cent Live 8 concert broadcasts, some just for the ...rheaded by former Boomtown Rat, Sir Bob Geldof. In...ook out for each other, while others look out for ...tural selection has designed individuals to behave...nd up with more resources and therefore more offsp...
... the loss of a gene called p63 accelerates aging i...n many organisms, including humans. Therefore, the...al role in aging-related processes. , "To study ho...inating it from adult mouse tissues. What struck u...e aging prematurely," says Alea Mills of Cold Spri...
Other Biology News:Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 2Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 3Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 4Helping in a selfish world 2Gene loss accelerates aging 2
Mouse Anti-Human Actopaxin, phospho (Ser8) Monoclonal Antibody, Unconjugated, Clone J160-366 from BD Biosciences Pharmingen
Anti-gp64 Antibody, Unconjugated from Novagen
Rabbit Anti-b-Catenin, phospho (Ser675) Antibody, Unconjugated from Spring Bioscience
Rabbit Anti-Human Naked1 Polyclonal Antibody, Unconjugated from Cell Signaling Technology
Biology Products: